GSK PLC closed 21.63% short of its 52-week high of £18.24, which the company reached on May 16th.

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.

The company, based in Dundee, Scotland, says it has already produced drug candidates for other clients in one quarter of the time normally needed. Exscientia and GSK aim to discover novel and ...

US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President. The Food ...

Commenting on the results, Bhushan Akshikar, MD of GlaxoSmithKline Pharmaceuticals, highlighted the company’s strategic initiatives in strengthening its market presence and enhancing access to ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

This was very lucrative, because her company ... owns GSK shares. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official ...

New York Post Entertainment has all the latest news on the royal family, from Kate Middleton and Prince William to King ...

A GSK logo is seen on the side of an office building in Poznan, Poland.